Molecular Features Underlying Discordance Between Clinical and Genomic Risk Stratification in Localized Prostate Cancer in Over 280, 000 Patients
INTRODUCTION: Although the Decipher Genomic Classifier (GC) improves risk stratification beyond standard National Comprehensive Cancer Network (NCCN) risk groups, distinct clinical discordance exists between them. Herein, we interrogate specific adverse molecular features (AMFs) associated with genomic upgrading/downgrading relative to clinical risk and evaluate their overall long-term prognostic impact on treated patients. MATERIALS AND METHODS: The specific prevalence of four separate AMFs (TP53 status, PTEN inactivation, lower androgen receptor [AR] activity, and RB1 loss) was evaluated across GC and NCCN risk groups using biopsy data from 287,145 patients. Prognostic associations with distant metastasis (DM) were fully assessed in 15,109 patients with NCCN high and very high-risk disease. RESULTS: Decipher re-classified 21% of NCCN low and favorable intermediate-risk patients as high risk, while 33% of NCCN high-risk patients were GC-lower risk. AMF prevalence associated more strongly with GC than NCCN groups. TP53 mutant-like status, PTEN inactivation, and lower AR activity were associated with NCCN-GC discordance. Within the study cohort, a high GC score was associated with significantly increased risk of DM; AMFs independently predicted DM. Patients with at least one adverse AMF and a GC score >0.60 had a predicted 5-year DM probability of 17-25%, compared to 5% for those with favorable molecular profiles and a GC score ≤0.60. CONCLUSIONS: Individual AMFs are associated with the discordance between NCCN and GC risk classifications. In patients with NCCN high-risk disease, the GC score serves as a primary prognostic driver, while AMF profiling provides additive risk stratification within specific clinical GC strata.
Authors
- Gerhardt Attard (ORCID: https://orcid.org/0000-0002-4811-7983)
- Krishnan R. Patel (ORCID: https://orcid.org/0000-0003-2120-1939)
- Edward M. Schaeffer (ORCID: https://orcid.org/0000-0003-0699-1899)
- Elai Davicioni (ORCID: https://orcid.org/0000-0001-9136-099X)
- Adam Benjamin Weiner (ORCID: https://orcid.org/0000-0002-1912-042X)
- Michael J. Zelefsky (ORCID: https://orcid.org/0009-0000-8873-3783)
- Mohammed Alshalalfa (ORCID: https://orcid.org/0000-0001-8405-3035)
- Ashley Evan Ross (ORCID: https://orcid.org/0000-0001-7044-9688)
- Angela Y. Jia (ORCID: https://orcid.org/0000-0002-0812-2614)
- Himanshu Nagar (ORCID: https://orcid.org/0000-0003-2381-6910)
- Hyunnam Monica Ryu (ORCID: https://orcid.org/0000-0002-8408-703X)
- Tyler M. Seibert (ORCID: https://orcid.org/0000-0002-4089-7399)
- Phuoc Tho Tran (ORCID: https://orcid.org/0000-0002-0147-0376)
- Xin Zhao (ORCID: https://orcid.org/0009-0001-6806-126X)
- Qi Xu (ORCID: https://orcid.org/0000-0002-4646-6936)
- Sarah Howlett (ORCID: https://orcid.org/0000-0002-2157-8819)
- Yang Liu (ORCID: https://orcid.org/0000-0003-1467-2652)
- Daniel Eidelberg Spratt (ORCID: https://orcid.org/0000-0002-5973-4741)
- Michael Leapman (ORCID: https://orcid.org/0000-0002-0727-7614)
- Melvin L.K. Chua (ORCID: https://orcid.org/0000-0002-1648-1473)
- David R. Wise (ORCID: https://orcid.org/0000-0003-3419-4723)
- Matthew R. Cooperberg (ORCID: https://orcid.org/0000-0003-4339-6685)
- James A. Proudfoot (ORCID: https://orcid.org/0009-0008-7063-5761)
- Marla K. Johnson (ORCID: https://orcid.org/0000-0002-5275-5558)
Institutions
- Northwestern University (US)
- University of Maryland, Baltimore (US)
- Cedars-Sinai Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of California, San Francisco (US)
- University Hospitals of Cleveland (US)
- Yale University (US)
- University of California San Diego (US)
- NYU Langone Health (US)
- Northwestern University (PH)
- University Hospitals Cleveland Medical Center (US)
- Veracyte (United States) (US)
- National Cancer Centre Singapore (SG)
- The London College (GB)
- Northwestern Medicine (US)
- University College London (GB)
- University of Maryland, College Park (US)
- University of San Francisco (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1158/1078-0432.ccr-26-2348
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00